News Treeline's $200m Series A extension, and other biofinancings Recent biotech financings include a $200m round for Treeline, with Enveda, Wugen, CHARM Therapeutics, and MRM Health also in on the action.
News AI specialist Charm Therapeutics launches with $50m Series A The UK's fertile environment for biotechs specialising in artificial intelligence has generated a new player – Charm Therapeutics – which came out of stealth mode this morning with a $50 mi
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.